Introduction
Human kininogens are multi-domain plasma proteins that are primarily synthesized in the liver (1, 2) . Both high-molecular-weight and low-molecular-weight kininogens are transcribed from a single gene via alternative splicing (3, 4) . Human highmolecular-weight kininogen (HK) serves as a cofactor for activation of prekallikrein and Factor XI (5, 6) . Activated prekallikrein cleaves HK, producing the two-chain kinin-free kininogen (HKa) and sequentially releasing the short-lived vasoactive agent bradykinin (7, 8) . HKa has properties of anti-adhesion, anti-platelet aggregation and anti-thrombosis, while bradykinin is a potent vasodilator and mediator of inflammation (9) .
In the process of identifying a serum marker for activation of the farnesoid X receptor (FXR), we observed that expression of the human kininogen gene was significantly increased by FXR agonists in primary human hepatocytes and in HepG2 cells (Cui et al, unpublished data) . Northern blot analysis confirmed the up-regulation of kininogen expression by FXR agonists.
FXR is a nuclear receptor for bile acids. The ligand-activated FXR regulates expression of a number of genes that are critically important for bile acid and cholesterol hemostasis (10) (11) (12) (13) . FXR heterodimerizes with the 9-cis-retinoic acid receptor (RXRα) (14, 15) , and the FXR/RXRα heterodimer activates gene transcription via binding to a specific DNA sequence comprised of two inverted hexamer-repeats separated by one nucleotide (IR-1) in the target promoter. To date, there is only one reported case where FXR down-regulates gene expression (apoA-I ) via FXR monomer or homodimer binding to an IR-1 (16). 7 NP_005114) into pcDNA3.1 at NheI/ HindIII. pGST-hFXR-LBD, pcDNA3.1-hRXRα and pCMV-lacZ were described previously (17) .
Kininogen Promoter Mutants. FXRE in the kininogen promoter was mutated using the Quick Change mutagenesis kit (Stratagene). PCR reactions were carried out according to the manufacturer's directions. The sense primer was 5'-ATGCAAATGAGC AAATTAACAA TTCCAGTGTTGC-3' and the antisense primer was 5'-GCAACACTG GAATTGTTAATTTGCTCATTTGCAT-3' (altered bases are in bold and underlined). (19) . The genomic sequences of human and mouse kininogen were compared using GLASS (20) . Putative binding sites for transcription factors were identified by searching against the TRANSFAC database (21) and the position weight matrices constructed internally.
Electrophoretic Mobility Shift Assays (EMSAs
Previous studies have identified multiple transcription start sites for human kininogen (4, 22) . To better define the transcription start sites of kininogen, we blasted the known human kininogen mRNA, NM_000893, against human mRNA and EST databases. More than 40 transcripts were identified. Mapping those transcripts to human genome indicated about 10 putative transcription start sites, among which the most upstream transcription start site was located 185 bp upstream from the translation start site. In our study, we refer to this site as the transcription start site of human kininogen.
Results

Endogenous Expression of Kininogen is Increased by FXR Agonists in Primary Human
Hepatocytes-Microarray analysis revealed that expression of kininogen is up-regulated by FXR agonists (Cui et al, unpublished data) . To confirm this observation, primary human hepatocytes were treated with various concentrations of CDCA, the most potent bile acid agonist of FXR, and the endogenous expression of kininogen was determined by real-time PCR (TaqMan). Consistent with the microarray result, kininogen mRNA was increased by CDCA in a dose-dependent manner with a half maximum (EC50) around 25
µM and a maximum induction of 8-to 10-fold (Fig. 1A ). This EC50 value correlates with the EC50 of CDCA in the FXR transactivation assay (23).
GW4064 is a potent and selective synthetic agonist of FXR (24) . To confirm that kininogen up-regulation by CDCA was mediated through FXR, primary human hepatocytes were treated with GW4064 and assayed for kininogen expression. Similar to the results of CDCA treatment, GW4064 also effectively increased kininogen mRNA in a dose-dependent manner with an EC50 about 0.1 µM (Fig. 1B) . Again, this value correlates well with the potency in FXR transactivation (23) . Taken together, these results suggest that kininogen up-regulation is mediated by FXR.
Primary human hepatocytes were treated with 60 µM CDCA and 5 µM GW4064 for 3, 6, 12, 24 and 48 hours to define the time kinetics for FXR-mediated kininogen gene regulation. Up-regulation was readily detectable within 3 hours with a maximum induction of 1.5 to 1.8-fold, which increased to 3-fold at 6 hours and 3.8-fold at 12 hours (Fig. 1C) . Twenty-four hour treatment yielded a 4 to 5-fold induction, which increased slightly at 48 hours (Fig. 1C) . The fact that kininogen up-regulation by FXR agonists was readily detectable at as early as 3 hours suggests kininogen as a direct target of FXR.
Endogenous Expression of Kininogen is Increased by FXR Agonists in HepG2 Cells-
HepG2 is a human hepatoma cell line that has been used to study FXR-mediated gene regulation. In HepG2, kininogen was expressed at a moderate level with an average threshold cycle of 24 in untreated cells (data not shown). This level of expression was comparable to that in primary hepatocytes (data not shown). Despite the relatively high basal expression in HepG2 cells, kininogen mRNA was robustly up-regulated by the FXR agonist CDCA or GW4064 in a dose-dependent fashion with a maximum induction of 130 to 140-fold ( Fig. 2A and 2B ).
Northern blot analysis was also carried out to confirm the results obtained from the real-time PCR. Treatment of HepG2 cells with 50 µM CDCA or 1 µM GW4064
resulted in an over 100-fold increase of two RNA bands at 3.6 kb and 1.5 kb respectively when probed with the radiolabeled human kininogen cDNA probe (Fig. 3) . The size of these two bands are consistent with those previously reported for high molecular weight and low molecular weight kininogen mRNA (22). One minor band at 2.6 kb was also slightly induced by FXR agonists (Fig. 3) . This RNA species is presumably the result of an alternative splicing of the kininogen gene. Northern blot analyses confirm that endogenous expression of kininogen is induced by FXR agonists.
The Kininogen Promoter Contains an IR-1 That Binds Specifically to the FXR/RXRα
Heterodimer-The FXR/RXRα heterodimer binds to specific DNA sequences in (Fig. 6 ). In the presence of 50 nM GW4064, this induction was further increased by 2 to 3-fold compared to that induced by 9-cis-RA alone (Fig. 6 ), indicating that FXR and RXRα ligands work additively on activation of kininogen promoter. These results confirm that FXR is a permissive receptor and that it is the FXR/RXRα heterodimer that transactivates the kininogen promoter.
Mutation of Kininogen IR-1 Abolishes Promoter Transactivation by FXR/RXRα-
Discussion
HKa has been shown to exert important functions in anti-adhesion (26) (27) (28) (29) , antiinflammation (30) and anti-platelet aggregation (31) . In addition, HKa has also been shown to be a mediator and modulator of vascular inflammation and local injury (9) . The short-lived vasodilator bradykinin stimulates the bradykinin B2 receptor on endothelial cells to produce nitric oxide (32, 33) . Bradykinin was reported to significantly affect renal hemodynamic and excretory function (34).
Although the structure and function of human kininogens have been extensively studied for over three decades, little is known about the gene regulation. Glucocorticoid was reported to increase HK synthesis in cultured hepatocytes (35) . Here we report the discovery of the kininogen gene as a novel direct target of FXR. Fold induction
